TY - JOUR
T1 - Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases
AU - Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative
AU - Levin, Seth N.
AU - Venkatesh, Shruthi
AU - Nelson, Katie E.
AU - Li, Yi
AU - Aguerre, Ines
AU - Zhu, Wen
AU - Masown, Karman
AU - Rimmer, Kathryn T.
AU - Diaconu, Claudiu I.
AU - Onomichi, Kaho B.
AU - Leavitt, Victoria M.
AU - Levine, Libby L.
AU - Strauss-Farber, Rebecca
AU - Vargas, Wendy S.
AU - Banwell, Brenda
AU - Bar-Or, Amit
AU - Berger, Joseph R.
AU - Goodman, Andrew D.
AU - Longbrake, Erin E.
AU - Oh, Jiwon
AU - Weinstock-Guttman, Bianca
AU - Thakur, Kiran T.
AU - Edwards, Keith R.
AU - Riley, Claire S.
AU - Xia, Zongqi
AU - De Jager, Philip L.
N1 - Publisher Copyright:
© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
PY - 2021/4
Y1 - 2021/4
N2 - Objective: To report initial results of a planned multicenter year-long prospective study examining the risk and impact of COVID-19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS). Methods: In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID-19 in persons with NID (PwNID) and change in their neurological care. Results: Our cohort included 1115 participants (630 NID, 98% MS; 485 reference) as of 30 April 2020. 202 (18%) participants, residing in areas with high COVID-19 case prevalence, met the April 2020 CDC symptom criteria for suspected COVID-19, but only 4% of all participants received testing given testing shortages. Among all participants, those with suspected COVID-19 were younger, more racially diverse, and reported more depression and liver disease. PwNID had the same rate of suspected COVID-19 as the reference group. Early changes in disease management included telemedicine visits in 21% and treatment changes in 9% of PwNID. After adjusting for potential confounders, increasing neurological disability was associated with a greater likelihood of suspected COVID-19 (ORadj = 1.45, 1.17–1.84). Interpretations: Our study of real-time, patient-reported experience during the COVID-19 pandemic complements physician-reported MS case registries which capture an excess of severe cases. Overall, PwNID seem to have a risk of suspected COVID-19 similar to the reference population.
AB - Objective: To report initial results of a planned multicenter year-long prospective study examining the risk and impact of COVID-19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS). Methods: In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID-19 in persons with NID (PwNID) and change in their neurological care. Results: Our cohort included 1115 participants (630 NID, 98% MS; 485 reference) as of 30 April 2020. 202 (18%) participants, residing in areas with high COVID-19 case prevalence, met the April 2020 CDC symptom criteria for suspected COVID-19, but only 4% of all participants received testing given testing shortages. Among all participants, those with suspected COVID-19 were younger, more racially diverse, and reported more depression and liver disease. PwNID had the same rate of suspected COVID-19 as the reference group. Early changes in disease management included telemedicine visits in 21% and treatment changes in 9% of PwNID. After adjusting for potential confounders, increasing neurological disability was associated with a greater likelihood of suspected COVID-19 (ORadj = 1.45, 1.17–1.84). Interpretations: Our study of real-time, patient-reported experience during the COVID-19 pandemic complements physician-reported MS case registries which capture an excess of severe cases. Overall, PwNID seem to have a risk of suspected COVID-19 similar to the reference population.
UR - https://www.scopus.com/pages/publications/85101275699
U2 - 10.1002/acn3.51314
DO - 10.1002/acn3.51314
M3 - Article
C2 - 33616290
AN - SCOPUS:85101275699
SN - 2328-9503
VL - 8
SP - 918
EP - 928
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 4
ER -